NCT06662097 A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery
| NCT ID | NCT06662097 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Alume Biosciences, Inc. |
| Condition | Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2024-10-16 |
| Primary Completion | 2025-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 64 participants in total. It began in 2024-10-16 with a primary completion date of 2025-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery
Eligibility Criteria
Inclusion Criteria: * Must be a minimum of 18 years of age * Study participant is planning to proceed with surgery * Willing to provide informed consent * Sexually active patients must be willing to use an acceptable form of contraceptive while participating and 30 days after. * Females of childbearing potential must have a negative pregnancy test at screening and during the study. Exclusion Criteria: * Patient has had prior surgery at the intended surgical site. * Patient has abnormal cardiac rhythm not controlled by medication. * Patient has moderate to severe renal impairment. * Patient has a history of fluorescein allergy. * Patient has a history of drug-related anaphylactic. * Presence of a concurrent disease or condition that may interfere with study participation. * Presence or history of any condition that, in the view of the investigator, places the patient at high risk of treatment compliance. * Use of any Investigational Product or investigational medial device within 30 days prior to screening.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06662097 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06662097 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06662097 currently recruiting?
Yes, NCT06662097 is actively recruiting participants. Contact the research team at barbara.stephens@alumebiosciences.com for enrollment information.
Where is the NCT06662097 trial being conducted?
This trial is being conducted at San Diego, United States.
Who is sponsoring the NCT06662097 clinical trial?
NCT06662097 is sponsored by Alume Biosciences, Inc.. The trial plans to enroll 64 participants.